Orion - Company Announcement

Orion and Wockhardt settle patent dispute

ORION CORPORATION:  ORION AND WOCKHARDT SETTLE PATENT DISPUTE

ORION CORPORATION STOCK EXCHANGE RELEASE 29 APRIL 2009 AT 10.40 A.M.

Orion and Wockhardt settle patent dispute

Orion Corporation ("Orion") and Wockhardt USA, LLC and Wockhardt
Limited (together "Wockhardt") today announce that they have executed
a settlement agreement on lawsuits filed by Orion in the United
States against Wockhardt regarding Wockhardt's submission of
abbreviated new drug applications ("ANDAs") for generic versions of
Orion's Comtan® and Stalevo® products. Comtan is used in the
treatment of Parkinson's disease as an adjunct to levodopa/carbidopa
therapy. Stalevo is a combination of carbidopa, levodopa and
entacapone for the treatment of Parkinson's disease. Both products
contain entacapone, a COMT enzyme inhibiting agent originated and
patented by Orion.

The first lawsuit was filed by Orion in the U.S. in 2007 and two
additional lawsuits were filed in 2008.  The settlement agreement
relates to all three suits. Under the terms of the settlement
agreement, Wockhardt will be able to launch generic versions of
Comtan and Stalevo on 30 September 2012, or possibly even earlier,
subject to certain conditions. The parties have agreed that Orion
will supply said generic product versions to Wockhardt. Except as
described, the terms of the settlement are confidential. The
settlement warrants no revision of the full-year outlook estimate
provided in the Interim Report 1-3/2009 of the Orion Group, published
on 27 April 2009.

Subject to the Court's approval, all three cases will be dismissed
and the patents remain in place, including U.S. Patent No. 5,446,194;
U.S. Patent No. 5,135,950; U.S. Patent No. 6,599,530; U.S. Patent No.
6,797,732; and U.S. Patent No. 6,500,867.

In compliance with the applicable U.S. laws, Orion will file all of
the above agreements with the United States Federal Trade Commission
and the United States Department of Justice.


Orion Corporation



Timo Lappalainen           Olli Huotari
President and CEO        SVP, Corporate Functions

Contact persons:
Olli Huotari, Senior Vice President, Corporate Functions, phone +358
10 426 3054, gsm +358 50 966 3054
Liisa Hurme, Senior Vice President, Proprietary Products, phone +358
10 426 2874, gsm +358 50 966 2874



About Orion
Orion is a European pharmaceuticals and diagnostics company dedicated
to treating and preventing disease by discovering and developing
innovative medicinal treatments and diagnostic tests for global
markets. Orion is engaged in human and veterinary drugs, active
pharmaceutical ingredients and diagnostic tests. In 2008, Orion's net
sales were EUR 710.7 million. Operating profit was EUR 184 million,
and the company invested EUR 99 million in pharmaceutical research
and development. The number of employees is about 3,100. Orion
corporate headquarters are in Espoo, Finland. Orion is listed on
NASDAQ OMX  Helsinki. For more information, please visit:
http://www.orion.fi/english/.





Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
Homepage: www.orion.fi